A multicentre, cross-sectional study on quality of life in patients with cutaneous lupus erythematosus

British Journal of Dermatology

Volumn 168, Issue 1, 2013, Pages 145-153

  Vasquez, R ^a   Wang, D ^a   Tran, Q P ^a   Adams Huet, B ^a   Chren, M M ^b   Costner, M I ^a   Cohen, J B ^a   Werth, V P ^c,d   Chong, Benjamin F ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Philadelphia VA Medical Center   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; STEROID; THALIDOMIDE;

ADULT; ALOPECIA; ANTIMALARIAL ACTIVITY; ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DISEASE SEVERITY; EDUCATIONAL STATUS; EMOTION; FEMALE; FUNCTIONAL STATUS; GENDER; HEALTH STATUS; HEALTH SURVEY; HUMAN; HUMAN RELATION; INCOME; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; SEXUAL FUNCTION; SHORT FORM 36; SKINDEX; SLEEP; SOCIAL INTERACTION; SOCIAL LIFE; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; WORK;

ACTIVITIES OF DAILY LIVING; CROSS-SECTIONAL STUDIES; EMOTIONS; FEMALE; HUMANS; INCOME; INTERPERSONAL RELATIONS; LUPUS ERYTHEMATOSUS, CUTANEOUS; MALE; MIDDLE AGED; MUSCULOSKELETAL PAIN; QUALITY OF LIFE; QUESTIONNAIRES; SICKNESS IMPACT PROFILE;

EID: 84872832867     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2012.11106.x     Document Type: Article

References (29)

1. Patel P, Werth V,. Cutaneous lupus erythematosus: a review. Dermatol Clin 2002; 20: 373-85.
2. Gilliam JN, Sontheimer RD,. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471-5.
3. Pinkus H,. Lichenoid tissue reactions. A speculative review of the clinical spectrum of epidermal basal cell damage with special reference to erythema dyschromicum perstans. Arch Dermatol 1973; 107: 840-6.
4. Sontheimer RD,. Subacute cutaneous lupus erythematosus: a decade's perspective. Med Clin North Am 1989; 73: 1073-90.
5. Callen JP,. Chronic cutaneous lupus erythematosus. Clinical, laboratory, therapeutic, and prognostic examination of 62 patients. Arch Dermatol 1982; 118: 412-6.
6. Rothfield N, March CH, Miescher P, et al. Chronic discoid lupus erythematosus. N Engl J Med 1963; 269: 1155-61.
7. Millard LG, Rowell NR,. Abnormal laboratory test results and their relationship to prognosis in discoid lupus erythematosus. A long-term follow-up study of 92 patients. Arch Dermatol 1979; 115: 1055-8.
8. Prystowsky SD, Gilliam JN,. Discoid lupus erythematosus as part of a larger disease spectrum. Correlation of clinical features with laboratory findings in lupus erythematosus. Arch Dermatol 1975; 111: 1448-52.
9. Tebbe B, Orfanos CE,. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 1997; 6: 96-104.
10. O'Quinn SE, Cole J, Many H,. Problems of disability and rehabilitation in patients with chronic skin diseases. Arch Dermatol 1972; 105: 35-41.
11. Klein R, Moghadam-Kia S, Taylor L, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011; 64: 849-58.
12. Piette EW, Foering KP, Chang AY, et al. Impact of smoking in cutaneous lupus erythematosus. Arch Dermatol 2012; 148: 317-22.
13. Ferraz LB, Almeida FA, Vasconcellos MR, et al. The impact of lupus erythematosus cutaneous on the quality of life: the Brazilian-Portuguese version of DLQI. Qual Life Res 2006; 15: 565-70.
14. Moghadam-Kia S, Chilek K, Gaines E, et al. Cross-sectional analysis of a collaborative web-based database for lupus erythematosus-associated skin lesions: prospective enrollment of 114 patients. Arch Dermatol 2009; 145: 255-60.
15. Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol 1996; 107: 707-13.
16. Ware JE Jr, Sherbourne CD,. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
17. McHorney CA, Ware JE Jr, Raczek AE,. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993; 31: 247-63.
18. Albrecht J, Taylor L, Berlin JA, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.
19. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-40.
20. Stewart AL, Ware JE,. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press, 1992.
21. Tarlov AR, Ware JE Jr, Greenfield S, et al. The Medical Outcomes Study. An application of methods for monitoring the results of medical care. JAMA 1989; 262: 925-30.
22. Wells KB, Burnam MA, Rogers W, et al. The course of depression in adult outpatients. Results from the Medical Outcomes Study. Arch Gen Psychiatry 1992; 49: 788-94.
23. Klein RS, Morganroth PA, Werth VP,. Cutaneous lupus and the Cutaneous Lupus Erythematosus Disease Area and Severity Index instrument. Rheum Dis Clin North Am 2010; 36: 33-51, vii.
24. Alarcon GS,. Lessons from LUMINA: a multiethnic US cohort. Lupus 2008; 17: 971-6.
25. Gaines E, Bonilla-Martinez Z, Albrecht J, et al. Quality of life and disease severity in a cutaneous lupus erythematosus pilot study. Arch Dermatol 2008; 144: 1061-2.
26. Eide MJ, Weinstock MA,. Association of UV index, latitude, and melanoma incidence in nonwhite populations-US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001. Arch Dermatol 2005; 141: 477-81.
27. Alarcon GS, McGwin G Jr, Roseman JM, et al. Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis Rheum 2004; 51: 609-15.
28. Finlay AY,. Quality of life measurement in dermatology: a practical guide. Br J Dermatol 1997; 136: 305-14.
29. Aberer E,. Epidemiologic, socioeconomic and psychosocial aspects in lupus erythematosus. Lupus 2010; 19: 1118-24.